Mylan's merger with Pfizer’s Upjohn division

Mylan’s merger with Pfizer’s Upjohn division involved joining forces to create a new company called Viatris in 2020. Upjohn was Pfizer’s unit dedicated to producing older, off-patent medicines. By merging, Mylan, known for generic drugs, combined with Upjohn’s portfolio to expand their global reach, improve efficiency, and better serve healthcare needs with a broader range of affordable medicines. This strategic move aimed to strengthen their position in the pharmaceutical industry, particularly in the generic and biosimilar markets, while offering more options to patients worldwide.